Research record
Nivolumab + ipilimumab
A combination of two immune checkpoint approaches. It can come up when a team is weighing intensity, potential benefit, and immune-related risk.
What this is
A combination of two immune checkpoint approaches. It can come up when a team is weighing intensity, potential benefit, and immune-related risk.
Why it may come up
- cannot be removed by surgery
- has spread
- combination immunotherapy
What not to assume
- Do not rank against PD-1 monotherapy in public copy without context.
At a glance
Nivolumab + ipilimumab
- Type
- Immunotherapy
- Mutation result
- any
- Where
- US, Korea, Japan, China, EU
- Evidence status
- Approved in listed place
- Last checked
- 2026-05-20
What we know
- NCI drug and PDQ sources list approved melanoma immunotherapy drugs and categories.
- The forum already has a cohort seed for lived experiences with this combination.
What is unclear
- Country-specific reimbursement and sequencing details remain to be mapped.
Questions to ask
- What is the goal of combination immunotherapy in this case?
- How are side effects monitored and handled by the team?
- What would make the team stop, pause, or change therapy?
Related cohort stories
Lived experience only
Experiences with nivolumab plus ipilimumab in melanoma
A cohort-style thread for families to describe questions, side effects discussed, and what changed during care.